Technical Analysis for VCNX - Vaccinex, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| See historical VCNX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 15 | 20 DMA Resistance | Bearish | 0.00% |
| Feb 15 | Doji - Bullish? | Reversal | 0.00% |
| Feb 14 | Fell Below 20 DMA | Bearish | 0.00% |
| Feb 14 | Outside Day | Range Expansion | 0.00% |
| Feb 13 | 20 DMA Support | Bullish | -2.87% |
| Feb 13 | Narrow Range Bar | Range Contraction | -2.87% |
| Feb 13 | Earnings Movers | Other | -2.87% |
| Feb 12 | Narrow Range Bar | Range Contraction | -2.78% |
| Feb 12 | Earnings Movers | Other | -2.78% |
| Feb 11 | Narrow Range Bar | Range Contraction | 0.00% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-19
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Biotechnology Health Cancer Biology Immunology Antibodies Immune System Monoclonal Antibodies Non Small Cell Lung Cancer Multiple Sclerosis Antibody Serious Diseases Melanoma Autoimmune Disorders Neurodegenerative Diseases Treatment Of Non Small Cell Lung Cancer Osteosarcoma Treatment Of Multiple Sclerosis Nsclc Seth Lederman Tolerx
Biotechnology Health Cancer Biology Immunology Antibodies Immune System Monoclonal Antibodies Non Small Cell Lung Cancer Multiple Sclerosis Antibody Serious Diseases Melanoma Autoimmune Disorders Neurodegenerative Diseases Treatment Of Non Small Cell Lung Cancer Osteosarcoma Treatment Of Multiple Sclerosis Nsclc Seth Lederman Tolerx
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more VCNX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.0 |
| 52 Week Low | 3.32 |
| Average Volume | 4,441 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 4.6695 |
| 20-Day Moving Average | 4.9418 |
| 10-Day Moving Average | 4.8685 |
| Average True Range | 0.3469 |
| ADX | 20.92 |
| +DI | 36.9955 |
| -DI | 17.0923 |
| Chandelier Exit (Long, 3 ATRs ) | 4.7193 |
| Chandelier Exit (Short, 3 ATRs ) | 5.1407 |
| Upper Bollinger Band | 5.3793 |
| Lower Bollinger Band | 4.5043 |
| Percent B (%b) | 0.45 |
| BandWidth | 17.706099 |
| MACD Line | 0.0739 |
| MACD Signal Line | 0.0643 |
| MACD Histogram | 0.0096 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.28 | ||||
| Resistance 3 (R3) | 5.32 | 5.23 | 5.21 | ||
| Resistance 2 (R2) | 5.23 | 5.14 | 5.21 | 5.19 | |
| Resistance 1 (R1) | 5.07 | 5.08 | 5.03 | 5.03 | 5.17 |
| Pivot Point | 4.98 | 4.98 | 4.96 | 4.96 | 4.98 |
| Support 1 (S1) | 4.82 | 4.89 | 4.78 | 4.78 | 4.63 |
| Support 2 (S2) | 4.73 | 4.83 | 4.71 | 4.61 | |
| Support 3 (S3) | 4.57 | 4.73 | 4.59 | ||
| Support 4 (S4) | 4.53 |
